Linking neuroscience with modern concepts of impulse control disorders in Parkinson's disease.
Identifieur interne : 000190 ( PubMed/Checkpoint ); précédent : 000189; suivant : 000191Linking neuroscience with modern concepts of impulse control disorders in Parkinson's disease.
Auteurs : T Celeste Napier [États-Unis] ; Jean-Christophe Corvol ; Anthony A. Grace ; Jamie D. Roitman ; James Rowe ; Valerie Voon ; Antonio P. StrafellaSource :
- Movement disorders : official journal of the Movement Disorder Society [ 1531-8257 ] ; 2015.
English descriptors
- KwdEn :
- Animals, Brain (drug effects), Brain (pathology), Disease Models, Animal, Dopamine Agonists (therapeutic use), Humans, Impulse Control Disorders (complications), Impulse Control Disorders (diagnosis), Impulse Control Disorders (drug therapy), Impulse Control Disorders (genetics), Impulsive Behavior (drug effects), Impulsive Behavior (physiology), Parkinson Disease (complications), Parkinson Disease (drug therapy), Parkinson Disease (genetics).
- MESH :
- chemical , therapeutic use : Dopamine Agonists.
- complications : Impulse Control Disorders, Parkinson Disease.
- diagnosis : Impulse Control Disorders.
- drug effects : Brain, Impulsive Behavior.
- drug therapy : Impulse Control Disorders, Parkinson Disease.
- genetics : Impulse Control Disorders, Parkinson Disease.
- pathology : Brain.
- physiology : Impulsive Behavior.
- Animals, Disease Models, Animal, Humans.
Abstract
Patients with Parkinson's disease (PD) may experience impulse control disorders (ICDs) when on dopamine agonist therapy for their motor symptoms. In the last few years, a rapid growth of interest for the recognition of these aberrant behaviors and their neurobiological correlates has occurred. Recent advances in neuroimaging are helping to identify the neuroanatomical networks responsible for these ICDs, and together with psychopharmacological assessments are providing new insights into the brain status of impulsive behavior. The genetic associations that may be unique to ICDs in PD are also being identified. Complementing human studies, electrophysiological and biochemical studies in animal models are providing insights into neuropathological mechanisms associated with these disorders. New animal models of ICDs in PD patients are being implemented that should provide critical means to identify efficacious therapies for PD-related motor deficits while avoiding ICD side effects. Here, we provide an overview of these recent advances, with a particular emphasis on the neurobiological correlates reported in animal models and patients along with their genetic underpinnings.
DOI: 10.1002/mds.26068
PubMed: 25476402
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:25476402Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Linking neuroscience with modern concepts of impulse control disorders in Parkinson's disease.</title><author><name sortKey="Napier, T Celeste" sort="Napier, T Celeste" uniqKey="Napier T" first="T Celeste" last="Napier">T Celeste Napier</name><affiliation wicri:level="2"><nlm:affiliation>Departments of Pharmacology and Psychiatry, Center for Compulsive Behavior and Addiction, Rush University Medical Center, Chicago, IL, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Departments of Pharmacology and Psychiatry, Center for Compulsive Behavior and Addiction, Rush University Medical Center, Chicago, IL</wicri:regionArea><placeName><region type="state">Illinois</region></placeName></affiliation></author><author><name sortKey="Corvol, Jean Christophe" sort="Corvol, Jean Christophe" uniqKey="Corvol J" first="Jean-Christophe" last="Corvol">Jean-Christophe Corvol</name></author><author><name sortKey="Grace, Anthony A" sort="Grace, Anthony A" uniqKey="Grace A" first="Anthony A" last="Grace">Anthony A. Grace</name></author><author><name sortKey="Roitman, Jamie D" sort="Roitman, Jamie D" uniqKey="Roitman J" first="Jamie D" last="Roitman">Jamie D. Roitman</name></author><author><name sortKey="Rowe, James" sort="Rowe, James" uniqKey="Rowe J" first="James" last="Rowe">James Rowe</name></author><author><name sortKey="Voon, Valerie" sort="Voon, Valerie" uniqKey="Voon V" first="Valerie" last="Voon">Valerie Voon</name></author><author><name sortKey="Strafella, Antonio P" sort="Strafella, Antonio P" uniqKey="Strafella A" first="Antonio P" last="Strafella">Antonio P. Strafella</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:25476402</idno><idno type="pmid">25476402</idno><idno type="doi">10.1002/mds.26068</idno><idno type="wicri:Area/PubMed/Corpus">000331</idno><idno type="wicri:Area/PubMed/Curation">000331</idno><idno type="wicri:Area/PubMed/Checkpoint">000190</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Linking neuroscience with modern concepts of impulse control disorders in Parkinson's disease.</title><author><name sortKey="Napier, T Celeste" sort="Napier, T Celeste" uniqKey="Napier T" first="T Celeste" last="Napier">T Celeste Napier</name><affiliation wicri:level="2"><nlm:affiliation>Departments of Pharmacology and Psychiatry, Center for Compulsive Behavior and Addiction, Rush University Medical Center, Chicago, IL, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Departments of Pharmacology and Psychiatry, Center for Compulsive Behavior and Addiction, Rush University Medical Center, Chicago, IL</wicri:regionArea><placeName><region type="state">Illinois</region></placeName></affiliation></author><author><name sortKey="Corvol, Jean Christophe" sort="Corvol, Jean Christophe" uniqKey="Corvol J" first="Jean-Christophe" last="Corvol">Jean-Christophe Corvol</name></author><author><name sortKey="Grace, Anthony A" sort="Grace, Anthony A" uniqKey="Grace A" first="Anthony A" last="Grace">Anthony A. Grace</name></author><author><name sortKey="Roitman, Jamie D" sort="Roitman, Jamie D" uniqKey="Roitman J" first="Jamie D" last="Roitman">Jamie D. Roitman</name></author><author><name sortKey="Rowe, James" sort="Rowe, James" uniqKey="Rowe J" first="James" last="Rowe">James Rowe</name></author><author><name sortKey="Voon, Valerie" sort="Voon, Valerie" uniqKey="Voon V" first="Valerie" last="Voon">Valerie Voon</name></author><author><name sortKey="Strafella, Antonio P" sort="Strafella, Antonio P" uniqKey="Strafella A" first="Antonio P" last="Strafella">Antonio P. Strafella</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="eISSN">1531-8257</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Brain (drug effects)</term><term>Brain (pathology)</term><term>Disease Models, Animal</term><term>Dopamine Agonists (therapeutic use)</term><term>Humans</term><term>Impulse Control Disorders (complications)</term><term>Impulse Control Disorders (diagnosis)</term><term>Impulse Control Disorders (drug therapy)</term><term>Impulse Control Disorders (genetics)</term><term>Impulsive Behavior (drug effects)</term><term>Impulsive Behavior (physiology)</term><term>Parkinson Disease (complications)</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (genetics)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Dopamine Agonists</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Impulse Control Disorders</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Impulse Control Disorders</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Brain</term><term>Impulsive Behavior</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Impulse Control Disorders</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Impulse Control Disorders</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Brain</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Impulsive Behavior</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Disease Models, Animal</term><term>Humans</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Patients with Parkinson's disease (PD) may experience impulse control disorders (ICDs) when on dopamine agonist therapy for their motor symptoms. In the last few years, a rapid growth of interest for the recognition of these aberrant behaviors and their neurobiological correlates has occurred. Recent advances in neuroimaging are helping to identify the neuroanatomical networks responsible for these ICDs, and together with psychopharmacological assessments are providing new insights into the brain status of impulsive behavior. The genetic associations that may be unique to ICDs in PD are also being identified. Complementing human studies, electrophysiological and biochemical studies in animal models are providing insights into neuropathological mechanisms associated with these disorders. New animal models of ICDs in PD patients are being implemented that should provide critical means to identify efficacious therapies for PD-related motor deficits while avoiding ICD side effects. Here, we provide an overview of these recent advances, with a particular emphasis on the neurobiological correlates reported in animal models and patients along with their genetic underpinnings.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">25476402</PMID><DateCreated><Year>2015</Year><Month>02</Month><Day>04</Day></DateCreated><DateCompleted><Year>2015</Year><Month>10</Month><Day>22</Day></DateCompleted><DateRevised><Year>2015</Year><Month>07</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1531-8257</ISSN><JournalIssue CitedMedium="Internet"><Volume>30</Volume><Issue>2</Issue><PubDate><Year>2015</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>Linking neuroscience with modern concepts of impulse control disorders in Parkinson's disease.</ArticleTitle><Pagination><MedlinePgn>141-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/mds.26068</ELocationID><Abstract><AbstractText>Patients with Parkinson's disease (PD) may experience impulse control disorders (ICDs) when on dopamine agonist therapy for their motor symptoms. In the last few years, a rapid growth of interest for the recognition of these aberrant behaviors and their neurobiological correlates has occurred. Recent advances in neuroimaging are helping to identify the neuroanatomical networks responsible for these ICDs, and together with psychopharmacological assessments are providing new insights into the brain status of impulsive behavior. The genetic associations that may be unique to ICDs in PD are also being identified. Complementing human studies, electrophysiological and biochemical studies in animal models are providing insights into neuropathological mechanisms associated with these disorders. New animal models of ICDs in PD patients are being implemented that should provide critical means to identify efficacious therapies for PD-related motor deficits while avoiding ICD side effects. Here, we provide an overview of these recent advances, with a particular emphasis on the neurobiological correlates reported in animal models and patients along with their genetic underpinnings.</AbstractText><CopyrightInformation>© 2014 International Parkinson and Movement Disorder Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Napier</LastName><ForeName>T Celeste</ForeName><Initials>TC</Initials><AffiliationInfo><Affiliation>Departments of Pharmacology and Psychiatry, Center for Compulsive Behavior and Addiction, Rush University Medical Center, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Corvol</LastName><ForeName>Jean-Christophe</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Grace</LastName><ForeName>Anthony A</ForeName><Initials>AA</Initials></Author><Author ValidYN="Y"><LastName>Roitman</LastName><ForeName>Jamie D</ForeName><Initials>JD</Initials></Author><Author ValidYN="Y"><LastName>Rowe</LastName><ForeName>James</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Voon</LastName><ForeName>Valerie</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Strafella</LastName><ForeName>Antonio P</ForeName><Initials>AP</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>088324</GrantID><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>DA027127</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>DA0331231</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>DA036328</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F31 DA033121</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MC_US_A060_0016</GrantID><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MH57440</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS074014</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>NS19608</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 NS074014</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 MH057440</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>12</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018491">Dopamine Agonists</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Neuropsychologia. 2011 Jul;49(9):2483-8</RefSource><PMID Version="1">21565210</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Behav Neurosci. 2011 Aug;125(4):492-500</RefSource><PMID Version="1">21604834</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurosci. 2011 Nov 30;31(48):17572-82</RefSource><PMID Version="1">22131418</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Parkinsonism Relat Disord. 2012 Jan;18(1):76-8</RefSource><PMID Version="1">21900033</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neuropsychopharmacology. 2012 May;37(6):1397-408</RefSource><PMID Version="1">22257895</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Parkinsonism Relat Disord. 2012 May;18(4):397-9</RefSource><PMID Version="1">22113132</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurosci. 2012 May 23;32(21):7316-24</RefSource><PMID Version="1">22623677</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neuroimage. 2012 Sep;62(3):1675-84</RefSource><PMID Version="1">22713671</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurobiol Dis. 2012 Dec;48(3):519-25</RefSource><PMID Version="1">22766031</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurology. 2013 Jan 8;80(2):176-80</RefSource><PMID Version="1">23296128</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nature. 2013 Feb 14;494(7436):238-42</RefSource><PMID Version="1">23354054</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Addiction. 2013 Apr;108(4):771-9</RefSource><PMID Version="1">23228208</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neural Transm. 2013 Apr;120(4):659-64</RefSource><PMID Version="1">23232664</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neural Transm. 2013 Apr;120(4):665-71</RefSource><PMID Version="1">23232665</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Behav Neurosci. 2013 Apr;127(2):245-55</RefSource><PMID Version="1">23565936</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Addict Biol. 2013 May;18(3):511-22</RefSource><PMID Version="1">22780124</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neuropsychopharmacology. 2013 May;38(6):996-1005</RefSource><PMID Version="1">23303045</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Parkinsonism Relat Disord. 2013 Jul;19(7):645-53</RefSource><PMID Version="1">23490464</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Int J Neuropsychopharmacol. 2013 Jul;16(6):1295-307</RefSource><PMID Version="1">23360787</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurophysiol. 2014 Jan;111(2):350-60</RefSource><PMID Version="1">24174652</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS One. 2014;9(1):e85747</RefSource><PMID Version="1">24465678</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Brain. 2014 Apr;137(Pt 4):1145-55</RefSource><PMID Version="1">24578545</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Hum Brain Mapp. 2014 Jun;35(6):2499-506</RefSource><PMID Version="1">24038587</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2014 Jun;29(7):904-11</RefSource><PMID Version="1">24832846</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Biol Psychiatry. 2015 Apr 15;77(8):740-8</RefSource><PMID Version="1">24655598</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2010 Aug 15;25(11):1660-9</RefSource><PMID Version="1">20589879</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neuropsychopharmacology. 2010 Oct;35(11):2155-64</RefSource><PMID Version="1">20631686</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2010 Oct 15;25(13):2203-10</RefSource><PMID Version="1">20721918</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurology. 2010 Nov 9;75(19):1711-6</RefSource><PMID Version="1">20926784</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2011 Feb 1;26(2):225-33</RefSource><PMID Version="1">21284039</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur J Neurol. 2011 May;18(5):703-10</RefSource><PMID Version="1">21073636</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur J Neurosci. 2007 Oct;26(7):2066-73</RefSource><PMID Version="1">17897403</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Biol Psychiatry. 2007 Nov 1;62(9):977-84</RefSource><PMID Version="1">17644072</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neuroimage. 2008 Jul 15;41(4):1352-63</RefSource><PMID Version="1">18485743</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurosci. 2008 Jul 30;28(31):7876-82</RefSource><PMID Version="1">18667619</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neuroimage. 2008 Aug 15;42(2):902-10</RefSource><PMID Version="1">18582578</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neuropsychopharmacology. 2008 Sep;33(10):2398-406</RefSource><PMID Version="1">18046307</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Trends Neurosci. 2008 Nov;31(11):552-8</RefSource><PMID Version="1">18786735</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurosci. 2008 Nov 19;28(47):12294-304</RefSource><PMID Version="1">19020023</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Behav Brain Res. 2000 Jun 1;110(1-2):73-81</RefSource><PMID Version="1">10802305</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Arch Gen Psychiatry. 2000 Jul;57(7):666-73</RefSource><PMID Version="1">10891037</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Am J Med Genet. 2000 Oct 9;96(5):665-70</RefSource><PMID Version="1">11054775</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Genet. 2001 Aug;60(2):107-16</RefSource><PMID Version="1">11553044</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Brain Cogn. 2002 Feb;48(1):195-211</RefSource><PMID Version="1">11812042</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurol Neurosurg Psychiatry. 2004 Apr;75(4):539-44</RefSource><PMID Version="1">15026491</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2004 Apr;19(4):397-405</RefSource><PMID Version="1">15077237</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neuropharmacology. 2004;47 Suppl 1:180-9</RefSource><PMID Version="1">15464136</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurosci. 1984 Nov;4(11):2866-76</RefSource><PMID Version="1">6150070</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurosci. 1984 Nov;4(11):2877-90</RefSource><PMID Version="1">6150071</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mol Chem Neuropathol. 1989 Jun;10(3):185-200</RefSource><PMID Version="1">2504173</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Trends Neurosci. 1990 Jul;13(7):290-6</RefSource><PMID Version="1">1695406</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Brain Res. 1990 Nov 19;533(2):203-12</RefSource><PMID Version="1">2126975</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Synapse. 1992 Feb;10(2):110-9</RefSource><PMID Version="1">1350111</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurosci. 1995 Sep;15(9):6157-66</RefSource><PMID Version="1">7666198</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Adv Pharmacol. 1998;42:686-90</RefSource><PMID Version="1">9327992</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Psychiatr Serv. 1998 Nov;49(11):1434-9</RefSource><PMID Version="1">9826244</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Psychopharmacology (Berl). 1998 Nov;140(2):233-42</RefSource><PMID Version="1">9860115</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Addiction. 1998 Sep;93(9):1375-84</RefSource><PMID Version="1">9926543</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Behav Brain Res. 1999 Apr;100(1-2):99-112</RefSource><PMID Version="1">10212057</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Behav Neurosci. 1999 Apr;113(2):283-90</RefSource><PMID Version="1">10357453</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Curr Opin Neurobiol. 2004 Dec;14(6):763-8</RefSource><PMID Version="1">15582381</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Psychopharmacology (Berl). 2005 Jun;179(4):791-803</RefSource><PMID Version="1">15887056</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nat Neurosci. 2005 Jun;8(6):805-12</RefSource><PMID Version="1">15908948</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neuron. 2005 Jul 21;47(2):255-66</RefSource><PMID Version="1">16039567</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neuropsychopharmacology. 2005 Sep;30(9):1724-34</RefSource><PMID Version="1">15827569</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur J Neurosci. 2006 Jan;23(2):552-60</RefSource><PMID Version="1">16420462</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Science. 2006 Feb 10;311(5762):861-3</RefSource><PMID Version="1">16469930</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurosci. 2006 Mar 1;26(9):2424-33</RefSource><PMID Version="1">16510720</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neuropsychopharmacology. 2006 Jul;31(7):1356-61</RefSource><PMID Version="1">16319915</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur J Neurosci. 2006 Oct;24(7):2098-104</RefSource><PMID Version="1">17067307</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Trends Neurosci. 2007 May;30(5):220-7</RefSource><PMID Version="1">17400299</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Trends Neurosci. 2007 May;30(5):203-10</RefSource><PMID Version="1">17400301</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Brain. 2009 May;132(Pt 5):1376-85</RefSource><PMID Version="1">19346328</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Psychopharmacology (Berl). 2009 Aug;205(2):273-83</RefSource><PMID Version="1">19404616</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2009 Sep 15;24(12):1803-10</RefSource><PMID Version="1">19562769</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neuropsychopharmacology. 2010 Jan;35(1):27-47</RefSource><PMID Version="1">19675534</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Neurol. 2009 Dec;66(6):817-24</RefSource><PMID Version="1">20035509</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Psychopharmacology (Berl). 2010 Jan;207(4):645-59</RefSource><PMID Version="1">19838863</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Arch Neurol. 2010 May;67(5):589-95</RefSource><PMID Version="1">20457959</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurobiol Dis. 2010 Jul;39(1):98-104</RefSource><PMID Version="1">20338240</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Arch Gen Psychiatry. 2010 Jun;67(6):624-30</RefSource><PMID Version="1">20530012</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Science. 2010 Jul 30;329(5991):532</RefSource><PMID Version="1">20671181</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurobiol Dis. 2010 Oct;40(1):216-21</RefSource><PMID Version="1">20594979</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Brain. 2011 May;134(Pt 5):1438-46</RefSource><PMID Version="1">21596771</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Neurol. 2011 Jun;69(6):986-96</RefSource><PMID Version="1">21416496</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurosci. 2011 Jun 22;31(25):9254-63</RefSource><PMID Version="1">21697375</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Exp Brain Res. 2011 Jul;212(3):371-84</RefSource><PMID Version="1">21643718</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D001921">Brain</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName><QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004195">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D018491">Dopamine Agonists</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D007174">Impulse Control Disorders</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName><QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D007175">Impulsive Behavior</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName><QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D010300">Parkinson Disease</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName></MeshHeading></MeshHeadingList><OtherID Source="NLM">NIHMS638089 [Available on 02/01/16]</OtherID><OtherID Source="NLM">PMC4318759 [Available on 02/01/16]</OtherID><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">6-OHDA</Keyword><Keyword MajorTopicYN="N">PET</Keyword><Keyword MajorTopicYN="N">basal ganglia</Keyword><Keyword MajorTopicYN="N">dopamine agonists</Keyword><Keyword MajorTopicYN="N">fMRI</Keyword><Keyword MajorTopicYN="N">imaging</Keyword><Keyword MajorTopicYN="N">l-dopa</Keyword><Keyword MajorTopicYN="N">pramipexole</Keyword><Keyword MajorTopicYN="N">prefrontal cortex</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>4</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2014</Year><Month>8</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>8</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="aheadofprint"><Year>2014</Year><Month>12</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>12</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>12</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>10</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>2</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25476402</ArticleId><ArticleId IdType="doi">10.1002/mds.26068</ArticleId><ArticleId IdType="pmc">PMC4318759</ArticleId><ArticleId IdType="mid">NIHMS638089</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>États-Unis</li></country><region><li>Illinois</li></region></list><tree><noCountry><name sortKey="Corvol, Jean Christophe" sort="Corvol, Jean Christophe" uniqKey="Corvol J" first="Jean-Christophe" last="Corvol">Jean-Christophe Corvol</name><name sortKey="Grace, Anthony A" sort="Grace, Anthony A" uniqKey="Grace A" first="Anthony A" last="Grace">Anthony A. Grace</name><name sortKey="Roitman, Jamie D" sort="Roitman, Jamie D" uniqKey="Roitman J" first="Jamie D" last="Roitman">Jamie D. Roitman</name><name sortKey="Rowe, James" sort="Rowe, James" uniqKey="Rowe J" first="James" last="Rowe">James Rowe</name><name sortKey="Strafella, Antonio P" sort="Strafella, Antonio P" uniqKey="Strafella A" first="Antonio P" last="Strafella">Antonio P. Strafella</name><name sortKey="Voon, Valerie" sort="Voon, Valerie" uniqKey="Voon V" first="Valerie" last="Voon">Valerie Voon</name></noCountry><country name="États-Unis"><region name="Illinois"><name sortKey="Napier, T Celeste" sort="Napier, T Celeste" uniqKey="Napier T" first="T Celeste" last="Napier">T Celeste Napier</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000190 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 000190 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:25476402
|texte= Linking neuroscience with modern concepts of impulse control disorders in Parkinson's disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:25476402" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |